Gwas To Function Twas

---
id: gwas-to-function-twas
name: GWAS to Function via TWAS
category: genomics_genetics
short-description: Identify causal genes and therapeutic targets from GWAS using transcriptome-wide association studies
detailed-description: "Identifies genes whose genetically regulated expression mediates disease risk and determines therapeutic directionality (inhibit vs activate). Combines TWAS association testing with colocalization analysis to distinguish causal genes from LD artifacts, Mendelian Randomization for causal inference, and druggability scoring for target prioritization. Use when you have genome-wide GWAS summary statistics (N > 5,000) and want to: (1) identify effector genes for drug targeting, (2) establish causal evidence for gene-disease relationships, or (3) prioritize targets by genetic support. Supports FUSION (comprehensive) and S-PrediXcan (fast) with GTEx v8 expression weights across 54 tissues."
starting-prompt: Find causal genes and therapeutic targets from my GWAS results . .
---

# GWAS to Function via TWAS

Identify genes whose genetically regulated expression is associated with disease risk, determine therapeutic directionality (inhibit vs. activate), and prioritize drug targets with causal genetic evidence using Transcriptome-Wide Association Study (TWAS) analysis.

**Key capabilities:**
- Dual TWAS tools: FUSION (comprehensive) and S-PrediXcan (fast, 10-100x faster)
- Therapeutic directionality: Determine inhibit vs. activate strategy for each gene
- Multi-tier analysis: Basic → Colocalization → Mendelian Randomization → Druggability
- Colocalization testing: Filters LD artifacts (up to 50% of TWAS hits), requires PP.H4 > 0.8
- Cross-tissue meta-analysis: S-MultiXcan across 54 GTEx v8 tissues
- Biopharma-ready reports: Excel workbooks with prioritized targets and confidence levels

## When to Use This Skill

Use this skill when:
- ✅ You have genome-wide GWAS summary statistics (N > 5,000 samples)
- ✅ Need to identify effector genes for non-coding GWAS variants
- ✅ Want to determine therapeutic strategy (inhibit vs. activate gene expression)
- ✅ Prioritizing drug targets by genetic evidence strength
- ✅ Validating existing targets with causal genetic evidence

Don't use this skill when:
- ❌ Only have significant loci (p < 5×10⁻⁸) without genome-wide data
- ❌ Sample size < 5,000 (insufficient power for TWAS)
- ❌ Need functional enrichment analysis → use [functional-enrichment-from-degs](../functional-enrichment-from-degs/)
- ❌ Working with individual-level genotypes → run GWAS first with [gwas-genotype-qc](../gwas-genotype-qc/)

**Data requirements:** Genome-wide GWAS summary statistics with columns: SNP, CHR, BP, A1, A2, BETA/OR, SE, P, N

## Installation

### Required Software

| Software | Version | License | Commercial Use | Installation |
|----------|---------|---------|----------------|--------------|
| FUSION | Latest | MIT | ✅ Permitted | https://github.com/gusevlab/fusion_twas |
| MetaXcan/S-PrediXcan | Latest | MIT | ✅ Permitted | `pip install metaxcan` |
| Python | ≥3.9 | PSF | ✅ Permitted | conda/pip |
| R | ≥4.0 | GPL | ✅ Permitted | CRAN (required for FUSION only) |

### Python Packages

```bash
pip install pandas numpy scipy plotnine plotnine-prism seaborn statsmodels metaxcan adjustText
```

**For detailed installation:** See [references/installation-guide.md](references/installation-guide.md) for FUSION setup, LD reference panels, and GTEx weight downloads.

**License compliance:** All tools permit commercial AI agent use.

## Inputs

**Required:**
- **GWAS summary statistics:** Genome-wide (not just significant loci)
  - Format: Tab or comma-delimited text (gzip supported)
  - Required columns: SNP, CHR, BP, A1, A2, BETA/OR, SE, P, N
  - Minimum sample size: N > 5,000 (recommended N > 10,000)
  - Genome build: GRCh37/hg19 or GRCh38 (must specify)

**Optional:**
- **Trait information:** Type (disease/quantitative), directionality (higher = risk/protective)
- **Tissue selection:** LDSC heritability enrichment results (from [gwas-heritability-ldsc](../gwas-heritability-ldsc/))
- **eQTL summary statistics:** For colocalization (GTEx v8 available via download)

## Outputs

**Tier 1 (Basic):** TWAS results per tissue, Manhattan/QQ plots (PNG/SVG)

**Tier 2 (+ Coloc):** PP.H4 scores for each gene, therapeutic recommendations (inhibit/activate)

**Tier 3 (+ MR):** Causal estimates with sensitivity analyses, MR summary Excel

**Tier 4 (+ Drug):** `reports/[trait]_Target_Report.xlsx` - Comprehensive Excel workbook with executive summary, TWAS results, colocalization evidence, therapeutic directionality, MR causal inference, and druggability scores

## Clarification Questions

Ask these questions before starting analysis:

1. **Input Files** (ASK THIS FIRST):
   - Do you have specific GWAS summary statistics file(s) to analyze?
   - If uploaded: Can you confirm this is genome-wide summary statistics (not just significant loci)?
   - Expected format: SNP, CHR, BP, A1, A2, BETA/OR, SE, P, N columns
   - **Or use example/demo data?** Example GWAS datasets can be downloaded for testing purposes
   - Minimum requirements: N > 5,000 samples, genome-wide coverage

2. **Trait Information:**
   - Trait type: Disease (binary) or quantitative trait?
   - Trait directionality: Is higher value "risk" or "protective"?
   - Sample size and ancestry composition?
   - Trait category: Cardiovascular, metabolic, neurological, immune, cancer, etc.?

3. **Tissue Selection Strategy:**
   - **Data-driven (LDSC):** Run LDSC partitioned heritability first (most rigorous, see [gwas-heritability-ldsc](../gwas-heritability-ldsc/))
   - **Biology-based:** Use known trait-tissue relationships (see [references/tissue_reference_guide.md](references/tissue_reference_guide.md))
   - **Comprehensive:** Test all 54 GTEx tissues via S-MultiXcan (discovery mode)

4. **Analysis Tier** (choose depth based on goals and confidence requirements):
   - **Tier 1 - Basic TWAS**: Association testing only, low-medium confidence
   - **Tier 2 - + Colocalization** (**RECOMMENDED**): Filters LD artifacts (PP.H4 > 0.8), medium-high confidence
   - **Tier 3 - + Mendelian Randomization**: Establishes causality, high confidence
   - **Tier 4 - + Druggability**: Full target prioritization report, very high confidence (gold standard)

5. **TWAS Tool Selection:**
   - **FUSION** (comprehensive): Multiple prediction models, built-in colocalization, requires R + >32GB RAM
   - **S-PrediXcan** (fast): MASHR model, 10-100x faster than FUSION, requires Python + <16GB RAM
   - See [references/fusion_best_practices.md](references/fusion_best_practices.md) and [references/spredixxcan_best_practices.md](references/spredixxcan_best_practices.md)

6. **Computational Resources:**
   - Local machine (<16GB RAM): S-PrediXcan, analyze <5 tissues
   - Server/HPC (>32GB RAM): FUSION or S-PrediXcan, parallelize across all tissues

## Standard Workflow

> **Note:** Run from the OmicsClaw root directory and add the workflow scripts to `sys.path`:
> ```python
> import sys; import os; sys.path.insert(0, os.path.abspath('knowledge_base/scripts/gwas-to-function-twas'))
> ```

🚨 **EXECUTE EXACTLY AS SHOWN - Do not modify these commands.**

**CRITICAL: Use relative paths (knowledge_base/scripts/gwas-to-function-twas/, references/). DO NOT construct absolute paths like /mnt/knowhow/ or /workspace/.**

**IMPORTANT: Call scripts via command line. DO NOT import and write inline Python code.**

### Phase 1: Data Preparation

**Step 1: Validate and harmonize GWAS summary statistics**

```bash
python scripts/validate_gwas_sumstats.py \
  --gwas gwas_sumstats.txt.gz \
  --min-n 5000 \
  --build GRCh37 \
  --output gwas_harmonized.txt
```

QC checks: Duplicate SNPs, allele harmonization, genomic inflation (λGC), LDSC intercept. For LDSC QC interpretation, see [references/ldsc_qc_guidelines.md](references/ldsc_qc_guidelines.md).

**Step 2: Select tissues for TWAS analysis**

Option A - Data-driven (after running [gwas-heritability-ldsc](../gwas-heritability-ldsc/)):
```bash
python scripts/select_reference_panel.py \
  --ldsc-results ../gwas-heritability-ldsc/twas_tissue_recommendations.csv \
  --output selected_tissues.txt
```

Option B - Biology-based:
```bash
python scripts/select_reference_panel.py \
  --trait-category cardiovascular \
  --top-n 5 \
  --output selected_tissues.txt
```

See [references/tissue_reference_guide.md](references/tissue_reference_guide.md) for trait-tissue mappings.

**Step 3: Download expression weights and LD reference panels**

See [references/installation-guide.md](references/installation-guide.md) for:
- GTEx v8 weight download links (FUSION: http://gusevlab.org/projects/fusion/, S-PrediXcan: https://predictdb.org/)
- LD reference panel setup (1000 Genomes EUR or FUSION LDREF)

### Phase 2: TWAS Association Testing

**Step 4: Run TWAS analysis**

Option A - FUSION (comprehensive):
```bash
python scripts/run_fusion.py \
  --gwas gwas_harmonized.txt \
  --weights weights/GTEx_v8/ \
  --tissues selected_tissues.txt \
  --ref-ld-panel LDREF/ \
  --output results/fusion/
```

Option B - S-PrediXcan (fast):
```bash
python scripts/run_spredixxcan.py \
  --gwas gwas_harmonized.txt \
  --weights weights/GTEx_v8/ \
  --tissues selected_tissues.txt \
  --output results/spredixxcan/
```

See [references/fusion_best_practices.md](references/fusion_best_practices.md) and [references/spredixxcan_best_practices.md](references/spredixxcan_best_practices.md) for tool-specific parameters.

**Step 5: Generate visualization plots**

```bash
python scripts/plot_twas_results.py \
  --twas-results results/fusion/Artery_Coronary_twas.txt \
  --gwas gwas_harmonized.txt \
  --output-dir figures/
```

Creates Manhattan plots, QQ plots, and regional association plots (PNG + SVG formats).

**Step 5b (Optional): Validate against published TWAS results**

```bash
python scripts/validate_with_twas_hub.py \
  --twas-results results/fusion/Artery_Coronary_twas.txt \
  --trait coronary_artery_disease \
  --tissue Artery_Coronary
```

See [references/twas_hub_validation_guide.md](references/twas_hub_validation_guide.md).

### Phase 3: Statistical Refinement (Tier 2+)

**Step 6: Colocalization analysis to filter LD artifacts**

```bash
python scripts/colocalization_analysis.py \
  --twas-results results/fusion/significant_genes.txt \
  --gwas gwas_harmonized.txt \
  --eqtl-dir eqtl_data/GTEx_v8/ \
  --tissue Artery_Coronary \
  --pp4-threshold 0.8 \
  --output coloc_results/
```

**CRITICAL:** Up to 50% of TWAS hits may be LD artifacts. Only genes with PP.H4 > 0.8 have strong colocalization evidence.

**Step 6b (Optional): Cross-tissue meta-analysis**

```bash
python scripts/run_smultixcan.py \
  --gwas gwas_harmonized.txt \
  --weights weights/GTEx_v8/ \
  --output results/smultixcan/
```

### Phase 4: Therapeutic Directionality

**Step 7: Interpret therapeutic strategy (inhibit vs. activate)**

```bash
python scripts/interpret_therapeutic_direction.py \
  --coloc-results coloc_results/high_confidence.txt \
  --trait-direction risk \
  --trait-name "Coronary Artery Disease" \
  --output therapeutic_recommendations.csv
```

Logic: Positive TWAS Z-score + risk trait → **INHIBIT** gene; Negative Z-score + risk trait → **ACTIVATE** gene.

See [references/therapeutic_interpretation_guide.md](references/therapeutic_interpretation_guide.md) for comprehensive directionality framework.

**Step 8: Multi-layer consistency check (eQTL + TWAS directionality)**

```bash
python scripts/multilayer_direction_analysis.py \
  --therapeutic-recs therapeutic_recommendations.csv \
  --gwas gwas_harmonized.txt \
  --eqtl-data eqtl_data/GTEx_v8/ \
  --twas-results results/fusion/ \
  --coloc-results coloc_results/ \
  --output multilayer_consistency.csv
```

Confidence levels: High (consistent + PP.H4 > 0.8), Medium (PP.H4 = 0.5-0.8), Low (inconsistent/poor coloc).

### Phase 5: Causal Validation (Tier 3+)

**Step 9: Mendelian Randomization for causal inference**

```bash
python scripts/mendelian_randomization.py \
  --genes therapeutic_recommendations.csv \
  --exposure-data eqtl_data/GTEx_v8/ \
  --outcome-data gwas_harmonized.txt \
  --methods ivw,egger,weighted_median \
  --output mr_results/
```

MR establishes causal directionality (gene expression → trait). Includes sensitivity analyses for pleiotropy.

See [references/mendelian_randomization_guide.md](references/mendelian_randomization_guide.md) for MR principles and interpretation.

### Phase 6: Druggability Assessment (Tier 4)

**Step 10: Druggability scoring**

```bash
python scripts/druggability_scoring.py \
  --genes multilayer_consistency.csv \
  --include-known-drugs \
  --output druggability_scores.csv
```

Scores based on: Protein class, known drugs, clinical precedent, assay availability.

**Step 11: Generate comprehensive target report**

```bash
python scripts/export_results.py \
  --twas-results results/fusion/ \
  --coloc-results coloc_results/ \
  --therapeutic-recs therapeutic_recommendations.csv \
  --mr-results mr_results/ \
  --druggability druggability_scores.csv \
  --trait "Coronary Artery Disease" \
  --output reports/CAD_Target_Report.xlsx
```

Creates publication-ready Excel workbook with executive summary, evidence layers, and prioritized targets.

**That's it! The scripts handle everything automatically.**

⚠️ **CRITICAL - DO NOT:**
- ❌ Write inline TWAS code → causes model mismatches, missing QC steps
- ❌ Write inline colocalization code → incorrect PP.H4 calculations, wrong priors
- ❌ Use absolute paths like `/mnt/knowhow/workflows/` → use relative paths `scripts/` exactly as shown
- ❌ Import script functions directly → use command-line interface for proper error handling and validation
- ❌ Skip phases based on tier → breaks dependency chain (e.g., Phase 4 requires Phase 3 colocalization results)

**Phase dependencies:**
- Phase 3 (Colocalization) requires Phase 2 TWAS results
- Phase 4 (Directionality) requires Phase 3 PP.H4 > 0.8 filtering
- Phase 5 (MR) requires Phase 4 directional interpretations
- Phase 6 (Druggability) requires Phase 5 causal evidence

**DO NOT skip phases or run out of order.**

## Common Issues

| Issue | Cause | Solution |
|-------|-------|----------|
| Genomic inflation (λGC > 1.1) | Population stratification or polygenicity | Run LDSC intercept test, check ratio < 0.15. See [references/ldsc_qc_guidelines.md](references/ldsc_qc_guidelines.md) |
| No significant genes | Insufficient power, wrong tissues, or no true signals | Try FDR correction instead of Bonferroni, verify tissue relevance, check GWAS has genome-wide significant hits |
| Poor colocalization (PP.H4 < 0.5) | LD artifacts (common, affects ~50% of TWAS hits) | Expected behavior - filter these genes out, keep only PP.H4 > 0.8 |
| Allele mismatch errors | Strand flips, allele coding differences | Use `harmonize_alleles()` in Step 1, remove ambiguous A/T and C/G SNPs |
| FUSION memory errors | Insufficient RAM for large chromosomes | Use S-PrediXcan instead (10-100x less memory), or run chromosome-by-chromosome |

For complete troubleshooting guide, see [references/troubleshooting_guide.md](references/troubleshooting_guide.md).

## Suggested Next Steps

After completing TWAS analysis:

1. **Functional validation:** Cross-reference with expression data, protein-protein interaction networks
2. **Pathway enrichment:** Use [functional-enrichment-from-degs](../functional-enrichment-from-degs/) on prioritized genes
3. **Variant annotation:** Link causal variants to regulatory elements with [genetic-variant-annotation](../genetic-variant-annotation/)
4. **Portfolio prioritization:** Rank targets by genetic evidence strength, druggability, and clinical precedent
5. **Literature review:** Check PubMed for supporting functional studies on top genes

## Related Skills

**Prerequisites:**
- [gwas-genotype-qc](../gwas-genotype-qc/) - Quality control for raw genotype data
- [gwas-heritability-ldsc](../gwas-heritability-ldsc/) - Tissue enrichment analysis for tissue selection

**Downstream analyses:**
- [functional-enrichment-from-degs](../functional-enrichment-from-degs/) - Pathway analysis for gene lists
- [genetic-variant-annotation](../genetic-variant-annotation/) - Functional annotation of causal variants

**Alternatives:**
- SMR (Summary-data-based MR) - Alternative TWAS approach with built-in MR
- FOCUS (Fine-mapping Of CaUsal gene Sets) - Fine-mapping extension for TWAS

## References

**Internal documentation:**
- [references/ldsc_qc_guidelines.md](references/ldsc_qc_guidelines.md) - LDSC intercept interpretation
- [references/tissue_reference_guide.md](references/tissue_reference_guide.md) - Trait-tissue mappings (GTEx v8)
- [references/fusion_best_practices.md](references/fusion_best_practices.md) - FUSION usage guidelines
- [references/spredixxcan_best_practices.md](references/spredixxcan_best_practices.md) - S-PrediXcan/S-MultiXcan guidelines
- [references/therapeutic_interpretation_guide.md](references/therapeutic_interpretation_guide.md) - Directionality → drug target framework
- [references/mendelian_randomization_guide.md](references/mendelian_randomization_guide.md) - MR principles and assumptions
- [references/twas_hub_validation_guide.md](references/twas_hub_validation_guide.md) - Comparison with published TWAS
- [references/troubleshooting_guide.md](references/troubleshooting_guide.md) - Common issues and solutions
- [references/installation-guide.md](references/installation-guide.md) - Detailed setup instructions

**Key papers:**
- **FUSION:** Gusev A, et al. (2016) *Nat Genet* 48:245-252. https://doi.org/10.1038/ng.3506
- **S-PrediXcan:** Barbeira AN, et al. (2018) *Nat Commun* 9:1825. https://doi.org/10.1038/s41467-018-03621-1
- **S-MultiXcan:** Barbeira AN, et al. (2019) *PLoS Genet* 15:e1007889
- **Colocalization:** Giambartolomei C, et al. (2014) *PLoS Genet* 10:e1004383
- **MR:** Hemani G, et al. (2018) *eLife* 7:e34408

**Online resources:**
- **FUSION:** http://gusevlab.org/projects/fusion/
- **MetaXcan:** https://github.com/hakyimlab/MetaXcan
- **PredictDB:** https://predictdb.org/ (GTEx v8 weights)
- **GTEx Portal:** https://gtexportal.org/
- **TWAS Hub:** http://twas-hub.org/ (published TWAS results)
- **MR-Base:** https://www.mrbase.org/